Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study

Journal of Rheumatology

Volumn 43, Issue 9, 2016, Pages 1713-1717

  Kavanaugh, Arthur ^a   McInnes, Iain B ^b   Mease, Philip J ^c   Hall, Stephen ^d   Chinoy, Hector ^e   Kivitz, Alan J ^f   Wang, Zailong ^g   Mpofu, Shephard ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f Altoona Center for Clinical Research   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biologics; Interleukin 17a; Psoriatic arthritis; Secukinumab; Tumor necrosis factor inhibitor

Indexed keywords

METHOTREXATE; PLACEBO; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED; RETREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84984999085     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.160275     Document Type: Article

References (8)

1. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
2. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
3. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013;25:287-96.
4. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii116-23.
5. Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 2015;34:1019-23.
6. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;386:1137-46.
7. Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol 2015;33:S104-8.
8. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013;65:1213-23.